Log in to search using one of your social media accounts:

 

Proton-Beam Therapy in Limited-Stage SCLC Shows Promising Efficacy

Proton-beam therapy was found to be safe for patients with limited-stage small-cell lung cancer in the first prospective registry study of the therapy, with only a small number of high-grade toxicities.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Tags: Lung Cancer News Radiation Oncology Source Type: news

Related Links:

AbstractThe prevalence of small cell lung cancer (SCLC) has declined in the U.S. as the prevalence of tobacco use has declined. However, a significant number of people in the U.S. are current or former smokers and are at risk of developing SCLC. Routine histological or cytological evaluation can reliably make the diagnosis of SCLC, and immunohistochemistry stains (thyroid transcription factor‐1, chromogranin, synaptophysin, and CD56) can be used if there is uncertainty about the diagnosis. Rarely do patients present with SCLC amendable to surgical resection, and evaluation requires a meticulous workup for extra‐thoraci...
Source: The Oncologist - Category: Cancer & Oncology Authors: Tags: Review, Lung Cancer Source Type: research
ConclusionsIFM monotherapy should not be used for refractory relapse or heavily treated SCLC, and no further investigation is required in these populations.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research
What are the different stages of small cell lung cancer (SCLC)? Dr. Laura Chow of Seattle Cancer Care Alliance explains how SCLC can progress and the associated stage, the treatment plan, and where re... Author: patientpower Added: 12/11/2017
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts
Dr. Laura Chow of Seattle Cancer Care Alliance explains the different types of lung cancer, their distinctive growth patterns and treatment methods available today.Get email alerts | http://www.pa...... Author: patientpower Added: 12/11/2017
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts
How can small cell lung cancer (SCLC) patients continue to enjoy life? Carly Ornstein shares how to manage symptoms, find a treatment goal, and get the right care.Get email alerts | http://www.pat...... Author: patientpower Added: 12/11/2017
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts
Authors: Welter S, Aigner C, Roesel C Abstract High grade lung neuroendocrine tumours are a heterogeneous subtype of pulmonary cancers including small cell lung cancer (SCLC) and large-cell neuroendocrine carcinoma (LCNEC). LCNEC represents approximately 2-3% of lung cancers, whereas SCLC represents 15-20% of lung cancers. Patients with SCLC and LCNEC have a poor prognosis compared with patients with non-small cell lung cancer (NSCLC). LCNEC is treated with primary surgical resection in stages I-II, which is similar to other NSCLCs. Neo-adjuvant treatment in stage III is similar to NSCLC but has not been well studi...
Source: Journal of Thoracic Disease - Category: Respiratory Medicine Tags: J Thorac Dis Source Type: research
Conclusions: We have found that transposons are not globally deregulated in lung cancer tissue, but that individual transposons are. Also, we have found the set of transposons under and over expressed in those cancers.
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Lung Cancer Source Type: research
Introduction: Gene expression analysis need to use reference genes (RGs) to normalize the measurements. Ideally, a RG should be expressed in the same degree in all the studied tissues, that is why housekeeping genes usually are used. But it has been demonstrated that they are less invariant than what was thought.Objectives: To find a set of RGs in lung cancer.Methods: RNA-seq reads of healthy and tumoral samples from EGA (17 patients with small-cell lung cancer [SCLC]) and NCBI (50 patients with adenocarcinoma lung cancer) repositories were downloaded. Reads were processed with a novel algorithm developed by us based on th...
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Lung Cancer Source Type: research
Background and Aim: Early and differential diagnosis, histological subtyping are important issues in the management of patients with lung cancer (LC). The aim of this study is to investigate the diagnostic value of a panel of serum tumor markers in newly diagnosed LC.Methods:Venous blood samples were collected from 99 patients with LC (42 adenocarcinoma, 35 squamous, and 22 small cell carcinoma) and from 30 patients with benign lung disease. Progastrin releasing peptide (PGRP), squamous cell carcinoma antigen (SCCAg), cytokeratin 19-fragments (CYFRA 21.1), human epididymis protein 4 (HE4), Chromogranin A (CgA) and neuron s...
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Lung Cancer Source Type: research
Introduction: Systemic anti-cancer treatment in the last weeks of life is considered an indicator of aggressive end of life care. Internationally, a rise in aggressive treatment is seen, but information for European lung cancer patients is lacking.Aim: We explored developments in treatment modalities and aggressive therapy for patients with metastatic lung cancer.Methods: Patients with metastatic lung cancer (2005-2013) who died ≤9 months from diagnosis were selected from the Netherlands Cancer Registry. Aggressive treatment was defined as any form of active cancer treatment in the last month of life.Results: The most p...
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Lung Cancer Source Type: research
More News: Cancer | Cancer & Oncology | Lung Cancer | Small Cell Lung Cancer | Study | Toxicology